Tags

Type your tag names separated by a space and hit enter

Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts.
Cancer Drug Resist 2019; 2:1153-1163CD

Abstract

Our genomic DNA is under constant assault from endogenous and exogenous sources, which needs to be resolved to maintain cellular homeostasis. The eukaryotic DNA repair enzyme Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the hydrolysis of phosphodiester bonds that covalently link adducts to DNA-ends. Tdp1 utilizes two catalytic histidines to resolve a growing list of DNA-adducts. These DNA-adducts can be divided into two groups: small adducts, including oxidized nucleotides, RNA, and non-canonical nucleoside analogs, and large adducts, such as (drug-stabilized) topoisomerase- DNA covalent complexes or failed Schiff base reactions as occur between PARP1 and DNA. Many Tdp1 substrates are generated by chemotherapeutics linking Tdp1 to cancer drug resistance, making a compelling argument to develop small molecules that target Tdp1 as potential novel therapeutic agents. Tdp1's unique catalytic cycle, which is centered on the formation of Tdp1-DNA covalent reaction intermediate, allows for two principally different targeting strategies: (1) catalytic inhibition of Tdp1 catalysis to prevent Tdp1-mediated repair of DNA-adducts that enhances the effectivity of chemotherapeutics; and (2) poisoning of Tdp1 by stabilization of the Tdp1- DNA covalent reaction intermediate, which would increase the half-life of a potentially toxic DNA-adduct by preventing its resolution, analogous to topoisomerase targeted poisons such as topotecan or etoposide. The catalytic Tdp1 mutant that forms the molecular basis of the autosomal recessive neurodegenerative disease spinocerebellar ataxia with axonal neuropathy best illustrates this concept; however, no small molecules have been reported for this strategy. Herein, we concisely discuss the development of Tdp1 catalytic inhibitors and their results.

Authors+Show Affiliations

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31875206

Citation

Brettrager, Evan J., and Robert C A M. van Waardenburg. "Targeting Tyrosyl-DNA Phosphodiesterase I to Enhance Toxicity of Phosphodiester Linked DNA-adducts." Cancer Drug Resistance (Alhambra, Calif.), vol. 2, 2019, pp. 1153-1163.
Brettrager EJ, van Waardenburg RCAM. Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts. Cancer Drug Resist. 2019;2:1153-1163.
Brettrager, E. J., & van Waardenburg, R. C. A. M. (2019). Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts. Cancer Drug Resistance (Alhambra, Calif.), 2, pp. 1153-1163. doi:10.20517/cdr.2019.91.
Brettrager EJ, van Waardenburg RCAM. Targeting Tyrosyl-DNA Phosphodiesterase I to Enhance Toxicity of Phosphodiester Linked DNA-adducts. Cancer Drug Resist. 2019;2:1153-1163. PubMed PMID: 31875206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts. AU - Brettrager,Evan J, AU - van Waardenburg,Robert C A M, Y1 - 2019/12/19/ PY - 2019/12/26/entrez PY - 2019/12/26/pubmed PY - 2019/12/26/medline KW - Camptothecins KW - DNA adducts KW - DNA metabolism KW - DNA topoisomerases KW - Etoposide KW - Tdp1 KW - chain terminating nucleotides/nucleoside analogs KW - drug development KW - oxidative DNA damage KW - small molecules SP - 1153 EP - 1163 JF - Cancer drug resistance (Alhambra, Calif.) JO - Cancer Drug Resist VL - 2 N2 - Our genomic DNA is under constant assault from endogenous and exogenous sources, which needs to be resolved to maintain cellular homeostasis. The eukaryotic DNA repair enzyme Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the hydrolysis of phosphodiester bonds that covalently link adducts to DNA-ends. Tdp1 utilizes two catalytic histidines to resolve a growing list of DNA-adducts. These DNA-adducts can be divided into two groups: small adducts, including oxidized nucleotides, RNA, and non-canonical nucleoside analogs, and large adducts, such as (drug-stabilized) topoisomerase- DNA covalent complexes or failed Schiff base reactions as occur between PARP1 and DNA. Many Tdp1 substrates are generated by chemotherapeutics linking Tdp1 to cancer drug resistance, making a compelling argument to develop small molecules that target Tdp1 as potential novel therapeutic agents. Tdp1's unique catalytic cycle, which is centered on the formation of Tdp1-DNA covalent reaction intermediate, allows for two principally different targeting strategies: (1) catalytic inhibition of Tdp1 catalysis to prevent Tdp1-mediated repair of DNA-adducts that enhances the effectivity of chemotherapeutics; and (2) poisoning of Tdp1 by stabilization of the Tdp1- DNA covalent reaction intermediate, which would increase the half-life of a potentially toxic DNA-adduct by preventing its resolution, analogous to topoisomerase targeted poisons such as topotecan or etoposide. The catalytic Tdp1 mutant that forms the molecular basis of the autosomal recessive neurodegenerative disease spinocerebellar ataxia with axonal neuropathy best illustrates this concept; however, no small molecules have been reported for this strategy. Herein, we concisely discuss the development of Tdp1 catalytic inhibitors and their results. SN - 2578-532X UR - https://www.unboundmedicine.com/medline/citation/31875206/Targeting_Tyrosyl-DNA_phosphodiesterase_I_to_enhance_toxicity_of_phosphodiester_linked_DNA-adducts L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31875206/ DB - PRIME DP - Unbound Medicine ER -